These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29391042)

  • 41. [Medical treatment of lymphatic filariasis].
    Hovette P; Laroche R; Verrot D; Molinier S; Touze JE
    Med Trop (Mars); 1991; 51(1):87-90. PubMed ID: 2072855
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A campaign of "communication for behavioural impact" to improve mass drug administrations against lymphatic filariasis: structure, implementation and impact on people's knowledge and treatment coverage.
    Ramaiah KD; Vijay Kumar KN; Hosein E; Krishnamoorthy P; Augustin DJ; Snehalatha KS; Nanda B; Das PK
    Ann Trop Med Parasitol; 2006 Jun; 100(4):345-61. PubMed ID: 16762115
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The development of albendazole for lymphatic filariasis.
    Horton J
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S33-40. PubMed ID: 19843396
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The sharp end - experiences from the Tanzanian programme for the elimination of lymphatic filariasis: notes from the end of the road.
    Malecela MN; Mwingira U; Mwakitalu ME; Kabali C; Michael E; Mackenzie CD
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S53-7. PubMed ID: 19843398
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Albendazole for lymphatic filariasis.
    Critchley J; Addiss D; Gamble C; Garner P; Gelband H; Ejere H;
    Cochrane Database Syst Rev; 2005 Oct; (4):CD003753. PubMed ID: 16235339
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mathematical models and lymphatic filariasis control: endpoints and optimal interventions.
    Michael E; Malecela-Lazaro MN; Kabali C; Snow LC; Kazura JW
    Trends Parasitol; 2006 May; 22(5):226-33. PubMed ID: 16564745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The global programme to eliminate lymphatic filariasis: health impact after 8 years.
    Ottesen EA; Hooper PJ; Bradley M; Biswas G
    PLoS Negl Trop Dis; 2008 Oct; 2(10):e317. PubMed ID: 18841205
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lymphatic filariasis elimination programme in Assam, India, needs change in mass drug administration strategy to target the focus of infection.
    Khan AM
    Indian J Med Res; 2018 Jan; 147(1):7-10. PubMed ID: 29749354
    [No Abstract]   [Full Text] [Related]  

  • 49. Lymphatic filariasis elimination programme in India: progress and challenges.
    Ramaiah KD
    Trends Parasitol; 2009 Jan; 25(1):7-8. PubMed ID: 19008150
    [No Abstract]   [Full Text] [Related]  

  • 50. The role of gender relations in uptake of mass drug administration for lymphatic filariasis in Alor District, Indonesia.
    Krentel A; Wellings K
    Parasit Vectors; 2018 Mar; 11(1):179. PubMed ID: 29530082
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A triple-drug treatment regimen to accelerate elimination of lymphatic filariasis: From conception to delivery.
    Weil GJ; Jacobson JA; King JD
    Int Health; 2020 Dec; 13(Suppl 1):S60-S64. PubMed ID: 33349879
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improving drug delivery strategies for lymphatic filariasis elimination in urban areas in Ghana.
    Biritwum NK; Garshong B; Alomatu B; de Souza DK; Gyapong M; Kyelem D
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005619. PubMed ID: 28493966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mass chemotherapy options to control lymphatic filariasis: a systematic review.
    Tisch DJ; Michael E; Kazura JW
    Lancet Infect Dis; 2005 Aug; 5(8):514-23. PubMed ID: 16048720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lymphatic filariasis: new insights into an old disease.
    Melrose WD
    Int J Parasitol; 2002 Jul; 32(8):947-60. PubMed ID: 12076624
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Global Programme to eliminate lymphatic filariasis: progress report on mass drug administration, 2010.
    Wkly Epidemiol Rec; 2011 Aug; 86(35):377-88. PubMed ID: 21887884
    [No Abstract]   [Full Text] [Related]  

  • 56. Repurposing auranofin as a lead candidate for treatment of lymphatic filariasis and onchocerciasis.
    Bulman CA; Bidlow CM; Lustigman S; Cho-Ngwa F; Williams D; Rascón AA; Tricoche N; Samje M; Bell A; Suzuki B; Lim KC; Supakorndej N; Supakorndej P; Wolfe AR; Knudsen GM; Chen S; Wilson C; Ang KH; Arkin M; Gut J; Franklin C; Marcellino C; McKerrow JH; Debnath A; Sakanari JA
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003534. PubMed ID: 25700363
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease.
    Ramaiah KD; Ottesen EA
    PLoS Negl Trop Dis; 2014 Nov; 8(11):e3319. PubMed ID: 25412180
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Major progress toward eliminating lymphatic filariasis.
    Ottesen EA
    N Engl J Med; 2002 Dec; 347(23):1885-6. PubMed ID: 12466515
    [No Abstract]   [Full Text] [Related]  

  • 59. Assessment of treatment impact on lymphatic filariasis in 13 districts of Benin: progress toward elimination in nine districts despite persistence of transmission in some areas.
    Boko-Collins PM; Ogouyemi-Hounto A; Adjinacou-Badou EG; Gbaguidi-Saizonou L; Dossa NI; Dare A; Ibikounle M; Zoerhoff KL; Cohn DA; Batcho W
    Parasit Vectors; 2019 May; 12(1):276. PubMed ID: 31146779
    [TBL] [Abstract][Full Text] [Related]  

  • 60. What Is Needed to Eradicate Lymphatic Filariasis? A Model-Based Assessment on the Impact of Scaling Up Mass Drug Administration Programs.
    Kastner RJ; Stone CM; Steinmann P; Tanner M; Tediosi F
    PLoS Negl Trop Dis; 2015; 9(10):e0004147. PubMed ID: 26451729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.